Content about PARSIPPANY

March 17, 2014

Pierre Fabre Dermatologies announced that it received authorization from the Food and Drug Administration to market the pediatric drug Hemangeol (propranolol hydrochloride).

CASTRES, France and PARSIPPANY, N.J. — Pierre Fabre Dermatologies announced that it received authorization from the Food and Drug Administration to market the pediatric drug Hemangeol (propranolol hydrochloride).

It is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy," the company said. Infantile hemangioma is a vascular benign tumor that affects 3% to 10% of newborns.

February 7, 2014

Novartis Consumer Health on Thursday announced that Todd Hutsko has been appointed head of sales U.S., effective March 1.

PARSIPPANY, N.J. — Novartis Consumer Health on Thursday announced that Todd Hutsko has been appointed head of sales U.S., effective March 1. 

Hutsko succeeds Roger Gravitte, who has been appointed operating unit head for UK/Ireland.

July 26, 2013

Anda VP purchasing Marc Falkin wrote in an email to coworkers and friends that he would begin working for Actavis as VP marketing, pricing and contract operations for the Parsippany, N.J.-based drug maker's generics business.

WESTON, Fla. — One of Anda's executives is moving to Actavis after 12 years at Anda.

Anda VP purchasing Marc Falkin has announced that he is leaving the company, and will join Actavis as VP marketing, pricing and contract operations for the Parsippany, N.J.-based drug maker's generics business. Anda executive director of purchasing Anthony Mihelich will assume Falkin's responsibilities in the interim.

 

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

Watson to change brand in 2013
PARSIPPANY, N.J. — Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said. Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission in October, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.


November 15, 2012

The Food and Drug Administration has approved a generic drug for leukemia made by a subsidiary of Par Pharmaceutical Cos.


FDA approves Par leukemia drug
WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a generic drug for leukemia made by a subsidiary of Par Pharmaceutical Cos.


Par said Oct. 25 that the FDA had approved Anchen Pharmaceuticals’ tretinoin capsules in the 10-mg strength.


The drug is a generic version of Roche’s Vesanoid, various versions of which have annual sales of about $29 million, according to IMS Health.



 

November 1, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

PARSIPPANY, N.J. – Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission earlier this month, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.

 

April 27, 2011

A drug designed to reduce the risk of premature birth among pregnant women has been submitted to the Food and Drug Administration for approval.

LIVINGSTON and PARSIPPANY, N.J. — A drug designed to reduce the risk of premature birth among pregnant women has been submitted to the Food and Drug Administration for approval.